DS
TBPH icon

David Shaw’s Theravance Biopharma TBPH Stock Holding History

David Shaw’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-16,800
Closed -$251K – 3998
2014
Q4 		$251K Hold
16,800
– – ﹤0.01% 3718
2014
Q3 		$387K Buy
+16,800
New +$487K ﹤0.01% 3537

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's TBPH Position: Q2 2026 in Review

David Shaw increased its Theravance Biopharma (TBPH) stake by 24% in Q2 2026, buying an estimated $3.83M and bringing the position to 1,185,390 shares worth $20.2M. The position accounts for 0.01% of the portfolio, ranked #1279.

David Shaw first reported a position in TBPH in Q2 2014 and has held it in 46 quarters since. The position peaked at $23.6M in Q4 2025. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • David Shaw held 1,185,390 shares of Theravance Biopharma worth $20.2M as of Q2 2026.
  • David Shaw bought 231,348 Theravance Biopharma shares in Q2 2026, an estimated $3.83M.
  • Theravance Biopharma made up 0.01% of David Shaw's portfolio in Q2 2026, its #1279 holding.
  • David Shaw first reported a position in Theravance Biopharma in Q2 2014 and has held it in 46 quarters since.
  • David Shaw's Theravance Biopharma position peaked at $23.6M in Q4 2025.
  • 178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.